Statement regarding the Pre and post market assessment of durable, implantable ventricular assist devices in the United States

Michael A. Acker*, Francis D. Pagani, Wendy Gattis Stough, Douglas L. Mann, Mariell Jessup, Robert Kormos, Mark S. Slaughter, Timothy Baldwin, Lynne Stevenson, Keith D. Aaronson, Leslie Miller, David Naftel, Clyde Yancy, Joseph Rogers, Jeffrey Teuteberg, Randall C. Starling, Bartley Griffith, Steven Boyce, Stephen Westaby, Elizabeth BlumePeter Wearden, Robert Higgins, Michael MacK

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The incorporation of complex medical device technologies into clinical practice is governed by critical oversight of the US Food and Drug Administration. This regulatory process requires a judicious balance between assuring safety and efficacy, while providing efficient review to facilitate access to innovative therapies. Recent contrasting views of the regulatory process have emphasized the difficulties in obtaining an optimal balance. Mechanical circulatory support has evolved to become an important therapy for patients who have advanced heart failure with the advent of more durable, implantable ventricular assist devices. The regulatory oversight of these new technologies has been difficult owing to the complexities of these devices, associated adverse event profile, and severity of illness of the intended patient population. Maintaining a regulatory environment to foster efficient introduction of safe and effective technologies is critical to the success of ventricular assist device therapy and the health of patients with advanced heart failure. Physicians representing key surgical and cardiology societies, and representatives from the Food and Drug Administration, National Heart Lung, and Blood Institute, Centers for Medicare and Medicaid Services, Interagency Registry of Mechanically Assisted Circulatory Support, and industry partners gathered to discuss relevant issues regarding the current regulatory environment assessing ventricular assist devices. The goal of the meeting was to explore innovative ways to foster the introduction of technologically advanced, safe, and effective ventricular assist devices. The following summary reflects opinions and conclusions endorsed by The Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, Heart Failure Society of America, International Society for Heart and Lung Transplantation, and Interagency Registry of Mechanically Assisted Circulatory Support.

Original languageEnglish (US)
Pages (from-to)2147-2158
Number of pages12
JournalAnnals of Thoracic Surgery
Issue number6
StatePublished - Dec 2012

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Statement regarding the Pre and post market assessment of durable, implantable ventricular assist devices in the United States'. Together they form a unique fingerprint.

Cite this